Emergent Biosolutions (EBS) Competitors

Emergent Biosolutions (NYSE:EBS) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Do analysts recommend EBS or JNJ?

Emergent Biosolutions currently has a consensus price target of $14.33, suggesting a potential upside of 95.28%. Johnson & Johnson has a consensus price target of $171.00, suggesting a potential upside of 9.01%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, analysts clearly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Johnson & Johnson	0 Sell rating(s)	11 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.55

Which has more volatility & risk, EBS or JNJ?

Emergent Biosolutions has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.

Which has preferable earnings & valuation, EBS or JNJ?

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$1.04B	0.38	-$190.60M	-$2.71	-2.71
Johnson & Johnson	$88.82B	4.25	$14.07B	$8.99	17.45

Do institutionals & insiders hold more shares of EBS or JNJ?

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 1.2% of Emergent Biosolutions shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media favor EBS or JNJ?

In the previous week, Johnson & Johnson had 121 more articles in the media than Emergent Biosolutions. MarketBeat recorded 127 mentions for Johnson & Johnson and 6 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.32 beat Emergent Biosolutions' score of 0.78 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Johnson & Johnson	107 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Is EBS or JNJ more profitable?

Johnson & Johnson has a net margin of 24.42% compared to Emergent Biosolutions' net margin of -13.63%. Johnson & Johnson's return on equity of 33.46% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-13.63%	-0.52%	-0.17%
Johnson & Johnson	24.42%	33.46%	13.30%

Summary

Johnson & Johnson beats Emergent Biosolutions on 12 of the 17 factors compared between the two stocks.